An algorithm to identify medication nonpersistence using electronic pharmacy databases

Journal of the American Medical Informatics Association

Volumn 22, Issue 5, 2015, Pages 957-961

  Parker, Melissa M ^a   Moffet, Howard H ^a   Adams, Alyce ^a   Karter, Andrew J ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

Computerized medical record systems; Diabetes mellitus; Electronic health record; Medication adherence; Medication nonpersistence

Indexed keywords

ADULT; BEHAVIOR; CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; HEALTH CARE SYSTEM; HUMAN; KAPPA STATISTICS; MAJOR CLINICAL STUDY; PHARMACY; ALGORITHM; DIABETES MELLITUS; DRUG DATABASE; ELECTRONIC MEDICAL RECORD; MEDICATION COMPLIANCE; VALIDATION STUDY;

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

ADULT; ALGORITHMS; ANTIHYPERTENSIVE AGENTS; DATABASES, PHARMACEUTICAL; DIABETES MELLITUS; ELECTRONIC HEALTH RECORDS; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; MEDICATION ADHERENCE; PHARMACIES;

EID: 84954223162     PISSN: 10675027     EISSN: 1527974X     Source Type: Journal    
DOI: 10.1093/jamia/ocv054     Document Type: Article

References (34)

1. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006; 166(17):1842-1847.
2. Lipska KJ, Wang Y, Kosiborod M, et al. Discontinuation of antihyperglycemic therapy and clinical outcomes after acute myocardial infarction in older patients with diabetes. Circ Cardiovasc Qual Outcomes. 2010;3(3):236-242.
3. Rodriguez LA, Cea-Soriano L, Martin-Merino E, Johansson S. Discontinuation of low dose aspirin and risk of myocardial infarction: casecontrol study in UK primary care. BMJ. 2011;343:d4094.
4. De Vera MA, Choi H, Abrahamowicz M, Kopec J, Goycochea-Robles MV, Lacaille D. Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2011;70(6):1020-1024.
5. Bauer AM, Parker MM, Schillinger D, et al. Associations between antidepressant adherence and shared decision-making, patient-provider trust, and communication among adults with diabetes: diabetes study of Northern California (DISTANCE). J Gen Intern Med. 2014;29(8):1139-1147.
6. Karter AJ, Parker MM, Moffet HH, Ahmed AT, Schmittdiel JA, Selby JV. New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res. 2009;44(5):1640-1661.
7. Caetano PA, Lam JM, Morgan SG. Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization. Clin Ther. 2006;28(9):1411-1424; discussion 1410.
8. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565-574; discussion 575-567.
9. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11(7):449-457.
10. Raebel MA, Schmittdiel J, Karter AJ, Konieczny JL, Steiner JF. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care. 2013;51(8 Suppl 3):S11-S21.
11. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-47.
12. Grey C, Jackson R, Wells S, et al. Maintenance of statin use over 3 years following acute coronary syndromes: a national data linkage study (ANZACSQI-2). Heart. 2014;100(10):770-774.
13. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care. 1988;26(8):814-823.
14. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation. J Clin Epidemiol. 2006;59(1):11-17.
15. Hudson M, Rahme E, Richard H, Pilote L. Comparison of measures of medication persistency using a prescription drug database. Am Heart J. 2007; 153(1):59-65.
16. Nielsen LH, Lokkegaard E, Andreasen AH, Hundrup YA, Keiding N. Estimating the effect of current, previous and never use of drugs in studies based on prescription registries. Pharmacoepidemiol Drug Saf. 2009;18(2): 147-153.
17. Liberman JN, Girdish C. Recent trends in the dispensing of 90-day-supply prescriptions at retail pharmacies: implications for improved convenience and access. Am Health Drug Benefits. 2011;4(2):95-100.
18. Delate T, Albrecht G, Olson KL. Out-of-plan pharmacy use by members of a managed care organization. Perm J. 2012;16(2):15-21.
19. Moffet HH, Adler N, Schillinger D, et al. Cohort Profile: The Diabetes Study of Northern California (DISTANCE)-objectives and design of a survey follow-up study of social health disparities in a managed care population. Int J Epidemiol. 2008;38(1):38-47.
20. Karter AJ, Moffet HH, Liu J, et al. Glycemic response to newly initiated diabetes therapies. Am J Manag Care. 2007;13(11):598-606.
21. Rector TS, Nugent S, Spoont M, Noorbaloochi S, Bloomfield HE. Screening electronic veterans' health records for medication discontinuation. Am J Manag Care. 2012;18(7):352-358.
22. Nielsen LH. Validation of methods for identifying discontinuation of treatment from prescription data. Appl Statist. 2010;59(Part 4):707-722.
23. Marcum ZA, Sevick MA, Handler SM. Medication nonadherence: a diagnosable and treatable medical condition. JAMA. 2013;309(20):2105-2106.
24. Brookhart MA, Patrick AR, Schneeweiss S, et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007;167(8): 847-852.
25. Karter AJ, Ackerson LM, Darbinian JA, et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry*. Am J Med. 2001;111:1-9.
26. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health. 1992;82:703-710.
27. Hiatt RA, Friedman GD. Characteristics of patients referred for treatment of end-stage renal disease in a defined population. Am J Public Health. 1982; 72:829-833.
28. Taitel M, Fensterheim L, Kirkham H, Sekula R, Duncan I. Medication days' supply, adherence, wastage, and cost among chronic patients in Medicaid. Medicare Medicaid Res Rev. 2012;2(3):E1-E13.
29. Garber MC, Nau DP, Erickson SR, Aikens JE, Lawrence JB. The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care. 2004;42(7):649-652.
30. Ho PM, Magid DJ, Masoudi FA, McClure DL, Rumsfeld JS. Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord. 2006;6:48.
31. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177-186.
32. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155(4):772-779.
33. Choo PW, Rand CS, Inui TS, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care. 1999;37(9):846-857.
34. Lau HS, de Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol. 1997;50(5):619-625.